NewLake Capital Partners (NLCP) Q3 2024 earnings summary

Executive summary

• Portfolio consists of 32 properties across 12 states, totaling 1.7 million sq ft, leased to 13 tenants under long-term triple-net leases, with a weighted average remaining lease term of 13.8 years and annual rent escalations of 2.6%.

• Q3 2024 revenue reached $12.6 million, up 9.3% year-over-year, driven by new acquisitions, rent escalators, and improved tenant payments.

• Net income attributable to common shareholders was $6.4 million ($0.31 per share), and AFFO was $10.8 million ($0.51 per share), both up 6.7% year-over-year.

• Dividend per share declared at $0.43 for Q3 2024, annualized at $1.72, with an 84% AFFO payout ratio.

• Industry headwinds include price compression, competition, regulatory uncertainty, and tenant payment issues, notably with Revolutionary Clinics and Calypso.

Financial highlights

• Q3 2024 revenue was $12.6 million, up from $11.5 million in Q3 2023.

• Net income for Q3 2024 was $6.4 million ($0.31 per diluted share), AFFO was $10.8 million ($0.51 per share), both up year-over-year.

• Dividend of $0.43 per share declared, with an 84% payout ratio and annualized yield of 10%.

• Gross real estate assets totaled $435 million; debt outstanding was $8 million.

• Liquidity stood at $102 million, including $19.8 million in cash and $82.4 million in credit facility capacity.

Outlook and guidance

• Management expects continued growth in medical cannabis, with positive legislative momentum for rescheduling and reform.

• Cash flow from operations and reserves are expected to fund operations, dividends, and debt service over the next twelve months.

• $12.2 million in unfunded commitments remain for development and improvement of cultivation facilities in Arizona and Connecticut.

• Company remains focused on disciplined capital deployment and maintaining strong liquidity.

• Federal reform catalysts include potential rescheduling, banking access, and decriminalization.